
New data show Zepbound/Mounjaro superior to Wegovy for weight loss
Eli Lilly’s Zepbound/Mounjaro (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide, also known as Ozempic), according to topline results from the SURMOUNT-5 Phase IIIb clinical trial. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. … Read More















